Philippe Duneton has more than 25 years’ experience in the fields of HIV/AIDS, infectious and tropical diseases and public health. Philippe has been at Unitaid since its creation in 2006. As Executive Director he has led Unitaid’s response to the COVID-19 pandemic, playing a vital role as the co-lead of the therapeutics arm of the Access to COVID Tools Accelerator. Previously, he was a practicing doctor at Hospital “La Pitié Salpétrière” in Paris (Infections Diseases Department) and was twice advisor to the French Ministry of Health under Minister Bernard Kouchner. He was the head of the Mission against HIV/AIDS and harm reduction for l’Assistance publique – Hôpitaux de Paris (AP-HP) and led the French regulatory agency for medicines and health products. He also chaired the Board of the European Medicines Agency. Philippe holds a Master’s degree in Public Health and is a Doctor.

Dr Alexandre Fraichard serves as Chief Executive Officer of genOway SA. He received a Doctorate in Philosophy in Molecular and Cellular Biology from Ecole Normale Superieure de Lyon in 1997. He then worked for five years on animal models at the ENS where he produced the first model of hypothyroidism and co-founded the Transgenetic Center. He completed his Masters of Business Administration degree at Hautes Etudes Commerciales, France in 1999 and co-founded the Company in 1999. He is currently also Chairman of Lab-Robot.

Bruno Jochum is the Executive Director and founder of the Climate Action Accelerator, a non-for-profit initiative based in Geneva aiming to support aid and health organisations to halve their emissions by 2030, turn them into vectors of change and share climate solutions as an open source common good within a transnational community of practice. 

Previously Director-General of Médecins sans Frontières Switzerland, he is the author of several articles on the humanitarian, health and aid dimensions of the climate crisis. He was a Global Fellow at the Geneva Centre for Security Policy in 2018-2019 and a regular contributor on climate at Geneva Solutions, an online media.

Bruno has extensive experience in the fields of humanitarian action and international health, crisis and instability situations, as well as expertise in the strategic steering of organizations and local government. He began working in the Horn of Africa in 1993 and during the Rwandan refugee crisis in Goma, and then joined MSF from 2001 to 2018 in various positions of responsibility, as head of mission in Iran, programme manager of portfolio of countries, director of operations, and then Director-General from 2011 until end 2017. He was part of the executive committee of MSF’s international movement, member of the boards of Epicentre, the Access Campaign for Essential Medicine and MSF Logistique.

He completed the Breakthrough Programme for Senior Executives at IMD Lausanne in 2017, holds a Masters’ degree in International Relations and International Law, after studying at the Institutes of Political Studies in Strasbourg and Paris.

Sarah Ouanhnon is Head of Net Zero Delivery and Partnerships in the Greener NHS Programme at NHS England where she leads the delivery of the NHS net zero commitment across Supply Chain and Medicines.  Her recent work includes the implementation of the NHS policy for high quality low carbon respiratory care, the development and implementation of the NHS Net Zero Supplier Roadmap, outlining requirements of NHS suppliers for the next ten years and the collaboration with the WHO and other healthcare systems to accelerate the decarbonisation of global healthcare supply chains. Sarah has 10 years of experience in managing large-scale change programmes in primary, acute and community care, as well as across systems.

Dr Luis Pizarro has led the Drugs for Neglected Diseases initiative (DNDi) since September 2022.

Dr Pizarro is a medical doctor and global health leader. He also serves as founder and member of the Global Health 2030 think tank, as scientific advisor for Global Health at Sciences Po Paris, and as board member of Sidaction. Having led medical projects for several years in West Africa, he became the first CEO of Solthis, from 2007 to 2019, successfully developing the international health and solidarity organization to become one of the leaders in health in West and Central Africa. In 2020, Dr Pizarro joined Unitaid’s leadership team during the COVID crisis to lead the international organization’s HIV portfolio and related access programmes. 

Born in Chile, and trained as a medical doctor at the University of Paris, he also holds a masters’ degree in Political Sciences from Sciences Po and an executive health MBA from a joint programme of EHESP School of Public Health, the London School of Economics, and the ESCP European Management School. 

Dr David Ripin is the Executive Vice President of Infectious Diseases, and the Chief Science Officer at the Clinton Health Access Initiative (CHAI). In these roles, he oversees CHAI’s work on increasing access to medicines and diagnostics for HIV, malaria, tuberculosis, and other disease areas through the use of sustainable market interventions. CHAI’s Access program has successfully implemented agreements with pharmaceutical companies to lower the price of key drugs and diagnostics by up to 80 percent, among other achievements. He also oversees the strategy and work of CHAI’s Malaria program.

Dr Ripin joined CHAI in 2007. Prior to assuming his current role, he led CHAI’s Pharmaceutical Sciences Team, which conducts research and development work. These efforts focus on reducing the cost of key drugs through recommending formulation, manufacturing process, and sourcing improvements, as well as conducting the transfer of these processes to manufacturing partners.

Dr Ripin is actively involved in setting international priorities for HIV drug optimization work, including organizing the Conference on Antiretroviral Drug Optimization in 2009. Before joining CHAI, he worked at Pfizer, Inc. for 10 years as part of the research and development group, focusing on the commercialization and manufacturing of drug candidates.